Governments have consistently approached change as a coordinated exercise, bundling multiple elements into single negotiations rather than adjusting one lever at a time. This pattern has shaped outcomes across pricing, pharmacy agreements, and the evolution of both off-patent and innovative medicine sectors, and it continues to define how the next phase of reform is likely to unfold.
Those who recognise and respond to the reality will be better positioned to shape reforms
March 31, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Medical research powering Australia’s health and economic future
March 31, 2026 - - Latest News -
A silent crisis in plain sight as arthritis burden grows while research funding falls behind
March 31, 2026 - - Latest News -
A new opportunity for biosimilars as sector leaders gather in Canberra
March 31, 2026 - - Latest News -
Those who recognise and respond to the reality will be better positioned to shape reforms
March 31, 2026 - - Latest News -
Alterity Therapeutics updates investors on key meeting with US regulator
March 30, 2026 - - Australian Biotech -
Aroa Biosurgery reports promising trial milestone for advanced wound treatment
March 30, 2026 - - Australian Biotech -
Genetic Signatures reshapes its business to cut costs and drive growth
March 30, 2026 -
